Chemical Property of Fondaparinux
Chemical Property:
- PSA：900.82000
- LogP:-9.34120
- Storage Temp.:2-8°C
- Solubility.:Water
- XLogP3:-14.7
- Hydrogen Bond Donor Count:19
- Hydrogen Bond Acceptor Count:52
- Rotatable Bond Count:30
- Exact Mass:1506.9513344
- Heavy Atom Count:91
- Complexity:3450
- Purity/Quality:
-
99% *data from raw suppliers
FondaparinuxSodium *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Drug Classes:Antithrombotic Agents
- Canonical SMILES:COC1C(C(C(C(O1)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)COS(=O)(=O)O)OC4C(C(C(C(O4)C(=O)O)OC5C(C(C(C(O5)COS(=O)(=O)O)O)O)NS(=O)(=O)O)O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O)NS(=O)(=O)O
- Isomeric SMILES:CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](O2)C(=O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COS(=O)(=O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COS(=O)(=O)O)O)O)NS(=O)(=O)O)O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O)NS(=O)(=O)O
- Recent ClinicalTrials:Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
- Recent EU Clinical Trials:A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19
- Recent NIPH Clinical Trials:Laboratory monitoring and the anti-coagulant effect of Fondaparinux after total knee arthroplasty
-
Description
Fondaparinux sodium was first introduced in the US for prophylaxis of deep vein
thrombosis which may lead to pulmonary embolism following major orthopaedic surgery.
Fondaparinux is the first of a new class of antithrombic agents distinct from low molecular
weight heparin (LMWH) and heparin. This entirely synthetic molecule is a copy of the
heparin pentasaccharide sequence, the shortest fragment able to catalyze antithrombin lllmediated
inhibition of factor Xa thereby inhibiting thrombin generation without antithrombin
action. Fondaparinux does not display significant effects on coagulation tests (such as activated partial thromboplastin time and prothrombin time), does not bind to platelet factor
4 or promote heparin-induced thrombocytopenia. In phase III studies, fondaparinux
significantly reduced the incidence of thromboembolism following orthopedic surgery, with
an overall risk reduction of 50% in comparison to the LMWH, enoxaparin. Following
subcutaneous administration, fondaparinux has a nearly complete bioavailability, a rapid
onset of action, a prolonged half-life (17.2 h) enabling once daily dosing and is not
metabolized preceeding renal excretion. The drug appears to be generally safe, with
haemoragic complications either comparable to or higher than those for LMWH.
-
Uses
Fondaparinux sodium has been used to test its neutralizing effect towards enterovirus D68-947 infection. It may be used in ultraviolet photodissociation (UVPD) measurements. Synthetic pentasaccharide corresponding to the anti-thrombin binding site of heparin. Anti-thrombotic.
-
Clinical Use
Prophylaxis of deep vein thrombosis
Treatment of deep vein thrombosis, pulmonary
embolism, unstable angina and after a myocardial
infarction
-
Drug interactions
Potentially hazardous interactions with other drugs
Increased risk of bleeding in combination with any
other drugs that affect coagulation.
